WallStreetZenWallStreetZen

NASDAQ: PCVX
Vaxcyte Inc Stock Forecast, Predictions & Price Target

Analyst price target for PCVX

Based on 6 analysts offering 12 month price targets for Vaxcyte Inc.
Min Forecast
$129.00+16.13%
Avg Forecast
$147.50+32.79%
Max Forecast
$163.00+46.74%

Should I buy or sell PCVX stock?

Based on 6 analysts offering ratings for Vaxcyte Inc.
Strong Buy
Strong Buy
3 analysts 50%
Buy
3 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their PCVX stock forecasts and price targets.

PCVX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-09-10
lockedlocked$00.00+00.00%2024-09-04Find Out Why
lockedlocked$00.00+00.00%2024-09-03
lockedlocked$00.00+00.00%2024-09-03
lockedlocked$00.00+00.00%2024-09-03
BTIG
Bottom 6%
6
Strong BuyMaintains$160.00+44.04%2024-09-03

1 of 1

Forecast return on equity

Is PCVX forecast to generate an efficient return?
Company
-32.96%
Industry
-762.05%
Market
49.3%
PCVX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PCVX forecast to generate an efficient return on assets?
Company
-31.36%
Industry
26.89%
PCVX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PCVX earnings per share forecast

What is PCVX's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
-$4.33
Avg 2 year Forecast
-$4.89
Avg 3 year Forecast
-$4.89

PCVX revenue forecast

What is PCVX's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$150.0M
Avg 2 year Forecast
$14.3M
Avg 3 year Forecast
$133.1M

PCVX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PCVX$111.08$147.50+32.79%Strong Buy
INSM$71.40$84.36+18.15%Strong Buy
INCY$67.04$71.90+7.25%Buy
BMRN$68.16$100.00+46.71%Strong Buy
TECH$74.00$82.80+11.89%Buy

Vaxcyte Stock Forecast FAQ

Is Vaxcyte Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: PCVX) stock is to Strong Buy PCVX stock.

Out of 6 analysts, 3 (50%) are recommending PCVX as a Strong Buy, 3 (50%) are recommending PCVX as a Buy, 0 (0%) are recommending PCVX as a Hold, 0 (0%) are recommending PCVX as a Sell, and 0 (0%) are recommending PCVX as a Strong Sell.

If you're new to stock investing, here's how to buy Vaxcyte stock.

What is PCVX's earnings growth forecast for 2024-2026?

(NASDAQ: PCVX) Vaxcyte's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.13%.

Vaxcyte's earnings in 2024 is -$497,188,000.On average, 5 Wall Street analysts forecast PCVX's earnings for 2024 to be -$482,823,437, with the lowest PCVX earnings forecast at -$569,209,322, and the highest PCVX earnings forecast at -$423,000,653. On average, 4 Wall Street analysts forecast PCVX's earnings for 2025 to be -$545,213,243, with the lowest PCVX earnings forecast at -$602,692,223, and the highest PCVX earnings forecast at -$484,385,972.

In 2026, PCVX is forecast to generate -$545,771,291 in earnings, with the lowest earnings forecast at -$635,059,028 and the highest earnings forecast at -$456,483,554.

What is PCVX's revenue growth forecast for 2026-2028?

(NASDAQ: PCVX) Vaxcyte's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.61%.

Vaxcyte's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast PCVX's revenue for 2026 to be $16,741,450,650, with the lowest PCVX revenue forecast at $16,741,450,650, and the highest PCVX revenue forecast at $16,741,450,650. On average, 1 Wall Street analysts forecast PCVX's revenue for 2027 to be $1,596,018,295, with the lowest PCVX revenue forecast at $1,596,018,295, and the highest PCVX revenue forecast at $1,596,018,295.

In 2028, PCVX is forecast to generate $14,849,666,727 in revenue, with the lowest revenue forecast at $1,596,018,295 and the highest revenue forecast at $28,103,315,158.

What is PCVX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: PCVX) forecast ROA is -31.36%, which is lower than the forecast US Biotechnology industry average of 26.89%.

What is PCVX's Price Target?

According to 6 Wall Street analysts that have issued a 1 year PCVX price target, the average PCVX price target is $147.50, with the highest PCVX stock price forecast at $163.00 and the lowest PCVX stock price forecast at $129.00.

On average, Wall Street analysts predict that Vaxcyte's share price could reach $147.50 by Sep 10, 2025. The average Vaxcyte stock price prediction forecasts a potential upside of 32.79% from the current PCVX share price of $111.08.

What is PCVX's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: PCVX) Vaxcyte's current Earnings Per Share (EPS) is -$4.68. On average, analysts forecast that PCVX's EPS will be -$4.33 for 2024, with the lowest EPS forecast at -$5.10, and the highest EPS forecast at -$3.79. On average, analysts forecast that PCVX's EPS will be -$4.89 for 2025, with the lowest EPS forecast at -$5.40, and the highest EPS forecast at -$4.34. In 2026, PCVX's EPS is forecast to hit -$4.89 (min: -$5.69, max: -$4.09).

What is PCVX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: PCVX) forecast ROE is -32.96%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.